The cost-saving program that Biotage carried out and the synergistic effects that arose through the merger of Pyrosequencing, Personal Chemistry, and Biotage LLC achieved almost full effect in the ﬁrst quarter. Operating costs were SEK 72m for the quarter, in line with the full year target of SEK 300m.
Biotage has had an eventful 2005. We continued to strengthen the Discovery Chemistry business area by acquiring the American company, Argonaut Technologies and the Swiss company, Separtis. In the Biosystems business area, our sequencing technology, Pyrosequencing, attracted a lot of attention during the year, indicating that the technology is starting to strengthen its position on the market.
Biotage is a leading global supplier of instruments and consumables for medicinal chemistry. The Company is also a well-established supplier of products in analytical chemistry. Promising products for both separation and purification in production volumes are being evaluated. Biotage’s shares are listed on the Nasdaq OMX Stockholm Small Cap list
Biotage offers instruments and consumables within three areas – organic chemistry, analytical chemistry and process chemistry. These products are used across the world in everything from pharmaceutical development to the analysis of samples within the environmental and food sectors. Biotage’s shares are listed on the NASDAQ OMX Stockholm Small Cap list.
Biotage offers products and services within three areas – Organic Chemistry, Analytical Chemistry and Industrial Resins. The Company’s offering is oriented toward an international market, and the majority of the Company’s sales are generated outside Sweden. The Biotage share is listed on the NASDAQ OMX Stockholm Small Cap list.